Factor H Level Assay
Dense Deposit Disease, C3 Glomerulonephritis and atypical Hemolytic Uremic Syndrome
Complement Factor H (FH; MW: 155 kDa) is an important fluid-phase and cell-surface regulator of alternative pathway (AP) activity. Patients with FH mutations or FH autoantibodies may have reduced plasma FH levels and/or function, and are at-risk to develop atypical hemolytic uremic syndrome or C3 glomerulopathy.
Indications for screening
Testing is appropriate for patients with DDD, C3GN and aHUS.
MORL screening methodology
Enzyme-linked immunosorbent assay (ELISA)
Turnaround time
Turnaround time is ~2 weeks.
Sample Required
1 ml frozen EDTA plasma (please see testing requisition for specimen handling).
Cost & CPT Codes
The Clinical Diagnostics Service of the Molecular Otolaryngology & Renal Research Laboratories is a CLIA-approved, Joint Commission-accredited diagnostic laboratory.